Anacor Pharmaceuticals (ANAC) Posts Quarterly Earnings, Beats Estimates By $0.09 EPS
Anacor Pharmaceuticals (NASDAQ: ANAC) announced its earnings results on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. The company had revenue of $3.28 million for the quarter, compared to the consensus estimate of $3.25 million. During the same quarter in the previous year, the company posted ($0.52) earnings per share. The company’s revenue for the quarter was up 26.6% on a year-over-year basis.
On a related note, analysts at Canaccord Genuity cut their price target on shares of Anacor Pharmaceuticals from $9.00 to $5.00 in a research note to investors on Wednesday, January 30th. They now have a “buy” rating on the stock.
Anacor Pharmaceuticals (NASDAQ: ANAC) traded down 0.27% on Thursday, hitting $3.70. Anacor Pharmaceuticals has a 1-year low of $3.00 and a 1-year high of $7.18. The stock’s 50-day moving average is currently $3.77. The company’s market cap is $131.6 million.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.